Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Gland Pharma
Large Cap•4,351 Employees•IPO 2020
Current Price
₹1655.30
-11.7 (-0.7%)Updated
Today's Range
1638.3
₹1655.30
1699.9
52 Week Range
52W Low₹1277.80
52W High₹2131.00
₹1655.30
Downside29.54%
Upside28.74%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹30,213.86 Cr
Market Cap
Total market value of companyP/E Ratio
35.19
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
3.43
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹51.42
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
3.96%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
11.90%
ROCE
Return on Capital Employed. >15% is goodNet Margin
13.86%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
-2.21%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
16.36%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
7.41%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
49.90%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.03
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹555.41
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
51.80%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
3 points- •Gland Pharma boasts a robust 24% operating profit margin (OPM), showcasing strong operational efficiency and high profitability. This is further supported by a substantial 49.9% quarterly profit growth, indicating strong market demand and a promising future.
- •The company maintains a conservative financial strategy with a low debt-to-equity ratio of 0.03, minimizing financial risk and providing flexibility for future investments and expansion opportunities. This strong financial position enhances its resilience to economic downturns.
Weaknesses
5 points- •Gland Pharma's P/E ratio of 40.70 is notably higher than several peers like Cipla (23.71) and Dr Reddy's (18.09), suggesting a premium valuation. This requires strong sustained growth to justify the current price.
- •A recent decrease in promoter shareholding from 57.86% to 51.83% warrants monitoring. This trend requires further analysis to assess potential implications for company control and future strategic direction, impacting investor confidence.
Opportunities
3 points- •The robust 49.9% quarterly profit growth indicates strong market acceptance and potential for further expansion into new product lines or therapeutic areas, leveraging its operational efficiency.
- •With a low debt-to-equity ratio of 0.03, the company has significant financial flexibility to pursue strategic acquisitions or invest in R&D, driving future growth in the competitive pharma sector.
Threats
3 points- •The pharmaceutical industry faces intense competition and pricing pressures, which could impact Gland Pharma's margins and market share, especially for its generic injectable products.
- •Strict and evolving regulatory environments globally pose a continuous risk, potentially leading to increased compliance costs, delays in product approvals, or even product recalls for the company.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
Recent Insider Transactions
| Insider Name | Transaction Date | Filing Date | Total Shares | Change | Price | Action |
|---|---|---|---|---|---|---|
S SRINIVASA RAO | 26 Feb 2025 | 26 Feb 2025 | 2,850 | 2,800 | ₹542 | BUY |
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹1813.90 | +₹158.60 | +9.58% |
| R3 | ₹1752.30 | +₹97.00 | +5.86% |
| R2 | ₹1726.10 | +₹70.80 | +4.28% |
| R1 | ₹1690.70 | +₹35.40 | +2.14% |
| PIVOT | ₹1664.50 | 9.20 | 0.56% |
| CURRENT | ₹1655.30 | - | - |
| S1 | ₹1505.90 | -₹149.40 | -9.03% |
| S2 | ₹1567.50 | -₹87.80 | -5.30% |
| S3 | ₹1602.90 | -₹52.40 | -3.17% |
| S4 | ₹1629.10 | -₹26.20 | -1.58% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume+10.3% vs avg
0.82L
(11 Mar 2026)Delivery %-7.7% vs avg
42.1%
(11 Mar 2026)Avg Volume (20D)20-day average
0.75L
(11 Feb - 11 Mar)Avg Delivery %Trend ↓
49.9%
(11 Feb - 11 Mar)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Laurus Labs Ltd
883.00 %
Highest Dividend Yield
Glaxosmithkline Pharmaceuticals Ltd
3.32 %
Peer Comparison
| Company Name |
|---|
 Ajanta Pharma Ltd |
 Astrazeneca Pharma India Ltd |
 Cohance Lifesciences Ltd |
 Emcure Pharmaceuticals Ltd |
 ERIS Lifesciences Ltd |
 Glaxosmithkline Pharmaceuticals Ltd |
 Glenmark Pharmaceuticals Ltd |
 Ipca Laboratories Ltd |
 J B Chemicals & Pharmaceuticals Ltd |
 Laurus Labs Ltd |
 Pfizer Ltd |
 Piramal Pharma Ltd |
 Sun Pharmaceutical Industries Ltd |
 Wockhardt Ltd |
About
Gland Pharma Ltd
Gland Pharma Limited is a prominent pharmaceutical company specializing in the manufacturing and sale of injectable formulations. Its global reach extends to India, the United States, Europe, Canada, Australia, New Zealand, and other international markets, showcasing a significant international presence and distribution network. The company's business model centers around providing a diverse range of injectable medications to meet various therapeutic needs.
A core aspect of Gland Pharma's operations involves the research and development of active pharmaceutical ingredients (APIs). This includes the complex synthesis of molecules such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. This in-house capability allows for greater control over the quality and supply chain of their products, and signifies a commitment to innovation within the pharmaceutical sector.
The company's product portfolio caters to a wide spectrum of therapeutic areas. This includes anti-malarial, anti-infectives, anti-neoplastic, blood-related, cardiac, gastrointestinal, gynecological, hormonal, neuro/CNS, ophthalmological/otological, pain and analgesic, respiratory medications, and vitamins, minerals, and nutrient supplements. The breadth of therapeutic categories serviced indicates a commitment to addressing a variety of patient needs and healthcare challenges.
Beyond manufacturing and sales, Gland Pharma also offers contract development services. This suggests that the company not only produces its own injectable medications but also provides research and development support to other pharmaceutical entities. This additional revenue stream diversifies the company’s income and expands its role within the industry ecosystem.
Established in 1978 and headquartered in Hyderabad, India, Gland Pharma operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd. This affiliation with a larger parent company provides financial backing and potentially access to broader resources and markets, contributing to the company's ongoing success and expansion.
COMPANY FACTS - GLAND
Registered Address
Survey No. 143-148, 150 & 151, Near Gandimaisamma 'X' Roads, D.P. Pally, Dundigal Gandimaisamma Mandal Medchal-Malkajgiri District
Hyderabad
TELANGANA
IN
Tel: 914030510999
Website:https://glandpharma.com/
Investor Relations:http://glandpharma.com/investors/investors_annual_report
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 4,351
IPO Date: 20/11/2020
MANAGEMENT - GLAND
Mr. Srinivas Sadu
Executive Chairman of the Board
Mr. Shyamakant Giri
Chief Executive Officer
Mr. Ravi Mitra
Chief Financial Officer
Mr. Sampath Pallerlamudi
Compliance Officer, Company Secretary
Ms. Wei Huang
Non-Executive Director
Dr. Jia Ai Zhang
Non-Executive Director
Mr. Wenjie Zhang
Non-Executive Director
Mr. Satyanarayana Chavali
Non-Executive Independent Director
Ms. Naina Kidwai
Non-Executive Independent Director
Mr. Essaji Vahanvati
Non-Executive Independent Director
Mr. Udo Vetter
Non-Executive Independent Director
Investor Questions Answered
Gland Pharma Ltd (GLAND) Stock FAQs
Get answers to the most common questions about Gland Pharma Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Gland Pharma Ltd (GLAND) is ₹1,655.3. Today, the stock has declined by ₹11.70 (0.70%), trading in a range of ₹1,638.3 to ₹1,699.9. The stock opened at ₹1,669.9 with a trading volume of 1,73,345 shares.
Gland Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹30,213.86 crores, P/E ratio of 35.19, ROE of 3.96%, and ROCE of 11.90%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Gland Pharma Ltd (GLAND) is ₹2,131, while the 52-week low is ₹1,277.8. Currently trading at ₹1,655.3, the stock is 44.2% away from its 52-week low and 22.3% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Gland Pharma Ltd stock at ₹1,655.3 depends on multiple factors. The stock is currently trading with a P/E ratio of 35.19 and P/B ratio of N/A. Today's performance shows a loss of 0.70%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Gland Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,655.3, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Gland Pharma Ltd's key financial metrics include: P/E Ratio: 35.19, P/B Ratio: N/A, ROE: 3.96%, ROCE: 11.90%, Dividend Yield: 0.00%, EPS: ₹51.42, Book Value: ₹555.41, Debt-to-Equity: 0.03, and Current Ratio: N/A. The company's market cap stands at ₹30,213.86 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Gland Pharma Ltd stock opened at ₹1,669.9 and is currently trading at ₹1,655.3, showing a decline of ₹11.70 (0.70%). The intraday high is ₹1,699.9 and low is ₹1,638.3. The trading volume stands at 1,73,345 shares, indicating moderate market participation today.
Gland Pharma Ltd has a Price-to-Earnings (P/E) ratio of 35.19, which means investors are willing to pay ₹35.19 for every ₹1 of earnings. With an EPS of ₹51.42, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Gland Pharma Ltd has a market capitalization of ₹30,213.86 crores, making it a mid-cap company. Market cap is calculated by multiplying the current stock price (₹1,655.3) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Gland Pharma Ltd has a book value of ₹555.41 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹1,655.3, which is 198.0% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Gland Pharma Ltd has a Return on Equity (ROE) of 3.96% and Return on Capital Employed (ROCE) of 11.90%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Gland Pharma Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Gland Pharma Ltd has a debt-to-equity ratio of 0.03, which measures the company's financial leverage by comparing total debt to shareholders' equity. A low ratio suggests conservative financing with minimal debt. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Gland Pharma Ltd has an Earnings Per Share (EPS) of ₹51.42, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹1,655.3 and P/E ratio of 35.19, investors are paying 35.19 times the annual earnings per share. This strong EPS indicates robust profitability. Track EPS growth over quarters to assess earnings momentum.
Gland Pharma Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Gland Pharma Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Gland Pharma Ltd stock, consider: 1) Fundamental Analysis - Review P/E (35.19), ROE (3.96%), debt-to-equity (0.03), and growth rates. 2) Technical Analysis - Check 52-week range (₹1277.80 - ₹2131.00), moving averages, and chart patterns. 3) Valuation - Compare current price (₹1655.30) with book value (₹555.41) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Gland Pharma Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹1,655.3 is 165430x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Gland Pharma Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹1277.80 - ₹2131.00). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.03 indicates leverage. 4) Liquidity Risk - Based on trading volume of 1,73,345 shares. 5) Valuation Risk - P/E of 35.19 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Gland Pharma Ltd operates in the industry with key metrics: P/E ratio of 35.19, ROE of 3.96%, market cap of ₹30,213.86 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.03), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Gland Pharma Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹1,655.3, with a 52-week range of ₹1277.80 to ₹2131.00. Based on fundamentals like P/E (35.19), ROE (3.96%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Gland Pharma Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹1655.30. 2) Fundamental Deterioration - Declining ROE (currently 3.96%), increasing debt (D/E: 0.03), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Gland Pharma Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu